Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Adalimumab
Drug ID BADD_D00041
Description Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor [A39984], [A39999]. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA [A39983]. This drug is frequently known as _Humira_. It is produced by recombinant DNA technology using a mammalian cell expression system. This drug is available in a prefilled syringe form and convenient pen form for subcutaneous self-administered doses [A39983]. A new biosimilar to adalimumab, named _adalimumab-adaz_, was approved by the FDA on October 31, 2018. This biosimilar is known as _Hyrimoz_, and is a trademark of Novartis AG [L4799].
Indications and Usage For treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease.
Marketing Status Prescription
ATC Code L04AB04
DrugBank ID DB00051
KEGG ID D02597
MeSH ID D000068879
PubChem ID Not Available
TTD Drug ID D0K5KS
NDC Product Code 0074-0616; 0074-0243; 0074-1115; 0074-1117; 0074-2540; 0074-4339; 0074-0817; 0074-3799; 0074-0067; 0074-0554; 0074-1539; 50090-4487; 0074-2330; 69438-0003; 0074-0124; 58394-051
Synonyms Adalimumab | Humira | Adalimumab-adbm | Amjevita | Adalimumab-atto | Cyltezo | D2E7 Antibody | Antibody, D2E7
Chemical Information
Molecular Formula Not Available
CAS Registry Number 331731-18-1
SMILES Not Available
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Adenoma benign16.02.02.001--Not Available
Agranulocytosis01.02.03.001--Not Available
Alanine aminotransferase increased13.03.01.003--
Alopecia23.02.02.001--
Antinuclear antibody negative13.06.01.013--Not Available
Appendicitis11.01.07.001; 07.19.01.001--
Arrhythmia02.03.02.001--Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Arthropathy15.01.01.003--Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Atrial fibrillation02.03.03.002--
Back pain15.03.04.005--
Blood creatine phosphokinase increased13.04.01.001--
Bone disorder15.02.04.004--Not Available
Bronchitis22.07.01.001; 11.01.09.001--
Bronchospasm22.03.01.004; 10.01.03.012--
Cardiac arrest02.03.04.001--
Cataract06.06.01.001--
Cellulitis23.09.01.001; 11.02.01.001--Not Available
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.011--Not Available
Cholecystitis09.03.01.001--
Cholelithiasis09.03.01.002--Not Available
Condition aggravated08.01.03.004--Not Available
Confusional state17.02.03.005; 19.13.01.001--
Coronary artery disease24.04.04.006; 02.02.01.001--Not Available
Cutaneous vasculitis24.05.02.004; 23.06.02.001; 10.02.02.003--Not Available
Cystitis20.03.02.002; 11.01.14.001--
Dehydration14.05.05.001--
The 1th Page    1 2 3 4 5    Next   Last    Total 5 Pages